These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 35650238)

  • 1. The genomic landscape of cholangiocarcinoma reveals the disruption of post-transcriptional modifiers.
    Zhang Y; Ma Z; Li C; Wang C; Jiang W; Chang J; Han S; Lu Z; Shao Z; Wang Y; Wang H; Jiao C; Wang D; Wu X; Shen H; Wang X; Hu Z; Li X
    Nat Commun; 2022 Jun; 13(1):3061. PubMed ID: 35650238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholangiocarcinoma miscoding in hepatobiliary centres.
    Selvadurai S; Mann K; Mithra S; Bridgewater J; Malik H; Khan SA
    Eur J Surg Oncol; 2021 Mar; 47(3 Pt B):635-639. PubMed ID: 33032867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RBM10 C761Y mutation induced oncogenic ASPM isoforms and regulated β-catenin signaling in cholangiocarcinoma.
    Chang J; Zhang Y; Zhou T; Qiao Q; Shan J; Chen Y; Jiang W; Wang Y; Liu S; Wang Y; Yu Y; Li C; Li X
    J Exp Clin Cancer Res; 2024 Apr; 43(1):104. PubMed ID: 38576051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive analysis of genomic mutation signature and tumor mutation burden for prognosis of intrahepatic cholangiocarcinoma.
    Zhang R; Li Q; Fu J; Jin Z; Su J; Zhang J; Chen C; Geng Z; Zhang D
    BMC Cancer; 2021 Feb; 21(1):112. PubMed ID: 33535978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrative genomic analyses of European intrahepatic cholangiocarcinoma: Novel ROS1 fusion gene and PBX1 as prognostic marker.
    Plum PS; Hess T; Bertrand D; Morgenstern I; Velazquez Camacho O; Jonas C; Alidousty C; Wagner B; Roessler S; Albrecht T; Becker J; Richartz V; Holz B; Hoppe S; Poh HM; Chia BKH; Chan CX; Pathiraja T; Teo AS; Marquardt JU; Khng A; Heise M; Fei Y; Thieme R; Klein S; Hong JH; Dima SO; Popescu I; Hoppe-Lotichius M; Buettner R; Lautem A; Otto G; Quaas A; Nagarajan N; Rozen S; Teh BT; Goeppert B; Drebber U; Lang H; Tan P; Gockel I; Schumacher J; Hillmer AM
    Clin Transl Med; 2024 Jun; 14(6):e1723. PubMed ID: 38877653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular profiling and prognostic analysis in Chinese cholangiocarcinoma: an observational, retrospective single-center study.
    Zhang C; You X; Zhang Q; Wang D
    Invest New Drugs; 2024 Feb; 42(1):24-34. PubMed ID: 37975978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive characterization of viral integrations and genomic aberrations in HBV-infected intrahepatic cholangiocarcinomas.
    An J; Kim D; Oh B; Oh YJ; Song J; Park N; Kim HI; Kang HJ; Oh JH; Kim W; Lee E; Sung CO; Song GW; Kim DG; Yu E; Letouzé E; Zucman-Rossi J; Lee HC; Shim JH
    Hepatology; 2022 Apr; 75(4):997-1011. PubMed ID: 34478159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.
    Moeini A; Sia D; Zhang Z; Camprecios G; Stueck A; Dong H; Montal R; Torrens L; Martinez-Quetglas I; Fiel MI; Hao K; Villanueva A; Thung SN; Schwartz ME; Llovet JM
    J Hepatol; 2017 May; 66(5):952-961. PubMed ID: 28126467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DCLK1, a Putative Stem Cell Marker in Human Cholangiocarcinoma.
    Nevi L; Di Matteo S; Carpino G; Zizzari IG; Samira S; Ambrosino V; Costantini D; Overi D; Giancotti A; Monti M; Bosco D; De Peppo V; Oddi A; De Rose AM; Melandro F; Bragazzi MC; Faccioli J; Massironi S; Grazi GL; Panici PB; Berloco PB; Giuliante F; Cardinale V; Invernizzi P; Caretti G; Gaudio E; Alvaro D
    Hepatology; 2021 Jan; 73(1):144-159. PubMed ID: 32978808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histological and molecular characterization of intrahepatic bile duct cancers suggests an expanded definition of perihilar cholangiocarcinoma.
    Akita M; Sofue K; Fujikura K; Otani K; Itoh T; Ajiki T; Fukumoto T; Zen Y
    HPB (Oxford); 2019 Feb; 21(2):226-234. PubMed ID: 30170977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cholangiocarcinoma in Germany: Epidemiologic trends and impact of misclassification.
    Walter D; Ferstl P; Waidmann O; Trojan J; Hartmann S; Schnitzbauer AA; Zeuzem S; Kraywinkel K
    Liver Int; 2019 Feb; 39(2):316-323. PubMed ID: 30176117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genome wide DNA copy number analysis in cholangiocarcinoma using high resolution molecular inversion probe single nucleotide polymorphism assay.
    Arnold A; Bahra M; Lenze D; Bradtmöller M; Guse K; Gehlhaar C; Bläker H; Heppner FL; Koch A
    Exp Mol Pathol; 2015 Oct; 99(2):344-53. PubMed ID: 26260902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nestin may be a candidate marker for differential diagnosis between small duct type and large duct type intrahepatic cholangiocarcinomas.
    Sasaki M; Sato Y; Nakanuma Y
    Pathol Res Pract; 2024 Jan; 253():155061. PubMed ID: 38154357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intratumoral heterogeneity of intrahepatic cholangiocarcinoma.
    Walter D; Döring C; Feldhahn M; Battke F; Hartmann S; Winkelmann R; Schneider M; Bankov K; Schnitzbauer A; Zeuzem S; Hansmann ML; Peveling-Oberhag J
    Oncotarget; 2017 Feb; 8(9):14957-14968. PubMed ID: 28146430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aldehyde dehydrogenase 3B2 promotes the proliferation and invasion of cholangiocarcinoma by increasing Integrin Beta 1 expression.
    Wang Y; Li K; Zhao W; Liu Z; Liu J; Shi A; Chen T; Mu W; Xu Y; Pan C; Zhang Z
    Cell Death Dis; 2021 Dec; 12(12):1158. PubMed ID: 34907179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathologic classification of cholangiocarcinoma: New concepts.
    Nakanuma Y; Kakuda Y
    Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):277-93. PubMed ID: 25966428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual-Specificity Phosphatase 11 Is a Prognostic Biomarker of Intrahepatic Cholangiocarcinoma.
    Xu L; Wang P; Zhang W; Li W; Liu T; Che X
    Front Oncol; 2021; 11():757498. PubMed ID: 34660327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic and transcriptional alterations of cholangiocarcinoma.
    Ito T; Sakurai-Yageta M; Goto A; Pairojkul C; Yongvanit P; Murakami Y
    J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):380-7. PubMed ID: 24532422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical presentation, diagnosis and staging of cholangiocarcinoma.
    Forner A; Vidili G; Rengo M; Bujanda L; Ponz-Sarvisé M; Lamarca A
    Liver Int; 2019 May; 39 Suppl 1():98-107. PubMed ID: 30831002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The reality of cholangiocarcinoma in India- real world data from a tertiary referral centre.
    Patkar S; Gupta V; Khobragade K; Goel M
    HPB (Oxford); 2022 Sep; 24(9):1511-1518. PubMed ID: 35379594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.